Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Year: 2020
Type: article
Study design: Observational Study
Source: Psychotherapy and Psychosomatics
DOI: 10.1159/000510703
Language: English
Subfield: Toxicology
Domain: Life Sciences
Keywords: esketamine, treatment-resistant depression, post-marketing safety, adverse event signals, dissociation, sedation, suicidal ideation, suicide mortality, venlafaxine, mood stabilizers, FDA Adverse Event Reporting System, reporting odds ratio, information component, serious adverse events, sex differences in adverse events
Open Access status: closed
OpenAlex ID: W3082360571
